Olympus (OLYMY)
OTHER OTC:OLYMY
Want to see OLYMY full AI Analyst Report?
Top Page
Olympus
(OTC:OLYMY)
Select Model
Select Model
Rating:59Neutral
Price Target:
$11.00
▲(9.67% Upside)
Action:N/A
Date:06/20/26
The score is primarily supported by generally solid fundamentals and an improving balance sheet, but is held back by the latest year’s profitability and cash-flow deterioration and by weak technical momentum. Valuation is only moderately supportive given the P/E and modest dividend yield.
Positive Factors
Revenue Resilience
Sustained multi-year revenue growth indicates durable demand for core endoscopy and related products. Consistent top-line expansion supports installed-base value, recurring service and consumables pull-through, and provides a stable foundation for reinvestment over the next several months.
Negative Factors
Profitability Decline
A meaningful earnings step-down despite slightly higher revenue suggests margin pressure or rising costs. If margins remain compressed, the company’s ability to fund growth, reinvest in innovation, and restore prior return levels could be impaired over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Resilience
Sustained multi-year revenue growth indicates durable demand for core endoscopy and related products. Consistent top-line expansion supports installed-base value, recurring service and consumables pull-through, and provides a stable foundation for reinvestment over the next several months.
Read all positive factors
Olympus (OLYMY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.23B
Dividend YieldN/A
Average Volume (3M)3.80K
Price to Earnings (P/E)26.9
Beta (1Y)0.31
Revenue Growth2.16%
EPS Growth-40.36%
CountryUS
Employees29,297
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)102.53
Shares Outstanding1,114,485,700
10 Day Avg. Volume2,360
30 Day Avg. Volume3,798
Financial Highlights & Ratios
PEG Ratio-0.61
Price to Book (P/B)2.08
Price to Sales (P/S)1.67
P/FCF Ratio93.07
Enterprise Value/Market Cap164.42
Enterprise Value/Revenue2.05
Enterprise Value/Gross Profit3.05
Enterprise Value/Ebitda7.20
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.57
Revenue Forecast (FY)$6.67B
Olympus Business Overview & Revenue Model
Company Description
Olympus Corporation, alongside its affiliated companies, operates as a global enterprise specializing in the development and distribution of medical equipment. Its reach extends across Japan, the Americas, the Middle East, Asia, and Oceania. The c...
How the Company Makes Money
Olympus makes money primarily by selling medical technology products and associated services, with the largest revenue contribution coming from its endoscopy franchise. Key revenue streams include: (1) Capital equipment sales: revenue from selling...
Olympus Earnings Call Summary
Earnings Call Date:Feb 13, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Neutral
The call balanced significant near-term operational and regulatory challenges (FDA observations, product ship holds, one-off gross margin/COGS impacts, and increased restructuring provisioning) against clear signs of stabilization and management actions (China recovery, majority of products released, leadership changes, disciplined commercial remediation and maintained mid-term targets). Management emphasized these are addressable, one-off or execution-related issues and reiterated long-term margin and growth ambitions, but material short-term impacts keep the tone cautious.Positive Updates
China: Early Signs of Recovery
After several quarters of double-digit declines, China showed a turnaround with approximately 5–6% growth quarter-over-quarter following tightened go-to-market focus, local investments and weekly pipeline oversight.
Negative Updates
Revenue Guidance Revised Down 2% (Constant Currency)
The company revised its revenue guidance down by ~2% on a constant currency basis, citing ship holds and weaker execution in certain businesses as drivers.
Read all updates
Q3-2026 Updates
Positive
Negative
China: Early Signs of Recovery
After several quarters of double-digit declines, China showed a turnaround with approximately 5–6% growth quarter-over-quarter following tightened go-to-market focus, local investments and weekly pipeline oversight.
Read all positive updates
Company Guidance
Management revised constant‑currency revenue guidance down ~2% and framed near‑term outlook as a range (reflecting the dynamic timing of product releases), while reaffirming its midterm targets of mid‑single‑digit revenue growth and a 20%+ operating margin; key metrics called out included the company’s “3–4–5” mid‑range modeling with 100+ basis points of margin improvement annually from FY27, inspections at 8 facilities (U.S., Europe, Japan) with ~70% of ship‑hold products already released and ~30% still being remediated, an expected Q4 revenue impact from ship holds of about JPY 18 billion, structural‑reform costs provisioned at JPY 31 billion (revised up from JPY 12 billion) with ~90% booked this fiscal year and the previously announced JPY 24 billion reduction effect unchanged, China showing a recovery (management cited roughly 6% Q3 growth and expects mid‑single‑digit market growth), and that one‑time COGS pressure from disposals/field corrective actions drove the gross‑margin hit rather than a fundamental mix shift.Olympus Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
78
Positive
Cash Flow
56
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 902.45B | 1.01T | 997.33B | 881.92B | 750.12B | 797.41B |
| Gross Profit | 605.07B | 654.09B | 683.70B | 571.70B | 459.53B | 499.57B |
| EBITDA | 256.35B | 170.51B | 232.37B | 219.64B | 143.12B | 153.74B |
| Net Income | 130.77B | 68.17B | 117.86B | 115.97B | 12.92B | 51.67B |
Balance Sheet | ||||||
| Total Assets | 1.39T | 1.54T | 1.43T | 1.36T | 1.18T | 1.02T |
| Cash, Cash Equivalents and Short-Term Investments | 193.42B | 216.46B | 254.83B | 312.84B | 227.75B | 165.92B |
| Total Debt | 352.74B | 239.58B | 229.10B | 386.13B | 355.26B | 280.92B |
| Total Liabilities | 787.02B | 725.12B | 681.09B | 846.64B | 785.54B | 643.71B |
| Stockholders Equity | 604.47B | 812.04B | 751.73B | 510.17B | 394.33B | 370.75B |
Cash Flow | ||||||
| Free Cash Flow | 45.13B | 18.16B | 125.25B | 107.96B | 64.89B | 67.61B |
| Operating Cash Flow | 109.42B | 100.58B | 190.46B | 169.73B | 124.12B | 133.54B |
| Investing Cash Flow | -51.75B | -87.41B | -65.47B | -71.02B | -118.92B | -62.43B |
| Financing Cash Flow | -143.79B | -87.63B | -211.54B | -40.67B | 40.80B | -19.46B |
Olympus Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $22.78B | 18.13 | 19.24% | ― | 5.87% | 8.18% | |
72 Outperform | $9.72B | 15.96 | 25.35% | 0.65% | 10.05% | 23.59% | |
71 Outperform | $13.14B | 28.43 | 120.89% | ― | 24.19% | 20.19% | |
60 Neutral | $11.18B | 23.43 | 5.20% | ― | -0.37% | -70.42% | |
59 Neutral | $11.23B | 26.86 | 8.94% | ― | 2.16% | -40.36% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $10.27B | -9.33 | -16.43% | 2.75% | -4.79% | -78.01% |
* Healthcare Sector Average
OLYMY
Olympus
10.38
-2.54
-19.65%
BAX
Baxter International
19.89
-9.84
-33.11%
EHC
Encompass Health
98.03
-21.39
-17.91%
ICLR
Icon
146.00
-1.30
-0.88%
UTHR
United Therapeutics
536.59
250.20
87.36%
MEDP
Medpace Holdings
460.20
151.56
49.11%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.